Pharmedium Services Recalls Fentanyl Citrate/Bupivacaine HCl Injectable Due to Glass Particulate Contamination
Pharmedium Services, LLC initiated a Class II nationwide recall (D-1398-2016) for 940 bags of Fentanyl Citrate and Bupivacaine HCl injectable solution. The recall stemmed from active pharmaceutical ingredient (API) contamination with glass particulate, posing significant patient safety risks. This event underscores critical vulnerabilities in sterile compounding supply chains, demanding heightened scrutiny from procurement and regulatory teams.
FDA Class II Recall: Glass Particulate Contamination in Sterile Injectables
Pharmedium Services, LLC, based in Lake Forest, IL, initiated a Class II recall (D-1398-2016) on May 5, 2016, for a critical sterile injectable product: 2 mcg/mL Fentanyl Citrate and 0.16% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride. This product, supplied in 100 mL within 150 mL Baxter Intravia Bags (Service Code 2K8102, Rx Only) and compounded at their Memphis, TN facility, was distributed nationwide. The primary reason for this significant action was the presence of particulate matter, specifically glass particulate, contaminating the active pharmaceutical ingredient (API) used in production. A total of 940 bags across multiple lots (e.g., 160380168M, 160410137M, 160890187M) were affected, with expiration dates ranging from May 8, 2016, to June 28, 2016. For procurement directors and supply chain VPs, this event highlights the severe consequences of API quality failures, necessitating stringent vendor qualification and incoming material inspection protocols to safeguard patient safety and supply integrity. The recall, voluntarily initiated by Pharmedium Services, LLC via email notification, was ultimately terminated on March 6, 2018, indicating the immediate market removal and corrective actions were completed.
Operational Context: Risks in Compounded Sterile Product Manufacturing
The recalled product, a compounded sterile injectable containing Fentanyl Citrate and Bupivacaine HCl, underscores the unique challenges and heightened risks inherent in the compounding pharmacy sector. Pharmedium Services, LLC, operating from Lake Forest, IL, with compounding activities in Memphis, TN, specializes in preparing customized medications for patients. The contamination of the API with glass particulate before its use in sterile drug production represents a fundamental breakdown in quality control within the raw material supply chain or internal handling processes. For regulatory affairs heads and business development executives, this incident serves as a stark reminder that even with established compounding practices, the integrity of starting materials is paramount. The nationwide distribution pattern of the affected 940 bags meant a broad exposure risk across healthcare facilities. Ensuring the sterility and purity of compounded products, especially those administered intravenously like this Fentanyl/Bupivacaine combination, is non-negotiable. This event necessitates a re-evaluation of risk management strategies for all stakeholders involved in the supply and administration of compounded sterile preparations.
Supply Chain Vulnerabilities: Impact of API Contamination
The contamination of Fentanyl Citrate and Bupivacaine HCl API with glass particulate prior to its incorporation into sterile injectable drugs presents significant supply chain vulnerabilities for healthcare providers and procurement teams. Fentanyl Citrate and Bupivacaine HCl are critical anesthetic and analgesic agents, widely used in pain management and surgical settings. A Class II recall of 940 bags of this compounded product, distributed nationwide, would have necessitated immediate quarantine and return, potentially disrupting patient care pathways reliant on these specific formulations. For procurement directors, this incident emphasizes the imperative of a multi-layered quality assurance strategy that extends beyond the finished product to the raw material suppliers. Dependence on a single API source without robust qualification and ongoing monitoring can lead to widespread supply disruptions and patient safety concerns, even for compounded products. The financial and reputational costs associated with such recalls, including investigation, product retrieval, and potential litigation, are substantial, highlighting the commercial imperative of proactive supply chain risk mitigation.
Broader Industry Trends: Recurring Contamination Challenges
This Pharmedium Services recall, stemming from glass particulate contamination in a sterile injectable, is not an isolated incident within the broader pharmaceutical industry. Recent parallel events highlight a persistent challenge with contamination across various product categories. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, directly mirroring the critical nature of sterile product integrity. Furthermore, metallic contamination has led to nationwide Class II recalls for products like TopCare Antacids and Retail Business Services, LLC.'s Calcium Carbonate Antacids in June 2026, indicating systemic issues in manufacturing controls or raw material sourcing. While the specific contaminants and products differ, these incidents collectively underscore the pervasive risk of foreign matter in pharmaceutical supply chains. For business development executives and supply chain VPs, these trends mandate a proactive approach to quality management, including enhanced audit programs for contract manufacturers and API suppliers, investment in advanced detection technologies, and a strategic focus on supplier diversification to build resilience against such recurring quality failures.
Regulatory Compliance and Post-Recall Implications
The termination of the Class II recall for Pharmedium Services, LLC's Fentanyl Citrate and Bupivacaine HCl injectable on March 6, 2018, signifies that the immediate market action was completed and the FDA deemed the issue resolved. However, the long-term implications for regulatory affairs heads and procurement teams extend beyond the recall's closure. A Class II classification indicates that the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, but glass particulates in an injectable are a serious concern. Companies involved in compounding sterile products must demonstrate rigorous adherence to current Good Manufacturing Practices (cGMP) and maintain robust quality systems to prevent recurrence. This event serves as a critical data point for future supplier risk assessments. Any organization considering Pharmedium Services, LLC as a partner or supplier must conduct thorough due diligence, examining corrective and preventive actions implemented post-recall. The regulatory scrutiny following such an event can lead to increased inspections and a heightened expectation for compliance, impacting future market access and operational costs for the company involved and its downstream partners.